The Financial Post reports in its Tuesday, Jan. 23, edition that Gildan Activewear has accused a U.S. investment fund of breaking U.S. antitrust rules in increasing its interest in the company and raised concerns about its ability to request a special shareholder meeting to replace a majority of its board. A Canadian Press dispatch to the Post reports that Browning West is seeking the meeting to replace eight of the company's 11 board members including chairman Donald Berg, and reinstate Gildan co-founder Glenn Chamandy as chief executive officer. Gildan alleges the fund did not notify U.S. regulators and comply with a 30-day waiting period before it increased its interest in the company to the point where it could request the shareholder meeting. Browning West says it is seeking to invalidate its meeting request based on the false premise that it violated the U.S. Hart-Scott-Rodino Antitrust Improvements Act. In a letter to shareholders, it said it poses no substantive antitrust concerns to any concerned authority and accused the Gildan board of trying to avoid holding the special meeting. Several Gildan shareholders, including the company's largest, Jarislowsky Fraser, have sought to have Mr. Chamandy reinstated.